Summary:
The purpose of this study is to evaluate the long-term safety of BHV-3500 (Zavegepant) intranasal in the acute treatment of migraine.
Criteria:- 2-8 moderate to severe migraines/month within the last 3 months
- Migraine attacks present for more than 1 year with age of onset of migraines prior to 50 years of age
- Migraine attacks, on average, lasting about 4-72 hours if untreated
- Less than 15 days with headaches (migraine or non-migraine) per month in each of the 3 months prior to the screening visit
- Ability to distinguish migraine attacks from tension/cluster headaches
- Subjects with contraindications for use of triptans may be included provided they meet all other study entry criteria
Qualified Participants May Receive:
Compensation up to $1,100 over the study length (90 days).